Current Research Interests
Dr. Thomas Atkinson is a trained psychometrician and outcomes researcher with expertise in quantitative and qualitative methodology. He serves as the Co-Director of the MSK Patient-Reported Outcomes, Community Engagement, and Language Core Facility. In this role, Dr. Atkinson has led the mixed methods validation of numerous state-of-the-art PRO measures and served as an investigator to facilitate all aspects of the development of the NCI’s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Dr. Atkinson’s current line of independent research focuses on understanding how artificial intelligence, machine learning, and natural language processing-based techniques can be leveraged to help us better understand nuanced patient free text reporting of treatment- or disease-related symptoms or adverse events. This work seeks to improve the incorporation of patient voice into clinical decision-making.
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Thomas Atkinson discloses the following relationships and financial interests:
No disclosures meeting criteria for time period
The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at ecoi@mskcc.org.
View all disclosures
